Valuation : Novartis AG

Market Cap 290B 249B 234B 214B 401B 27,574B 404B 2,774B 1,079B 13,988B 1,088B 1,064B 46,295B P/E 2026 *
21.7x
P/E 2027 * 18.5x
Enterprise Value 322B 278B 261B 238B 447B 30,684B 450B 3,087B 1,200B 15,565B 1,211B 1,184B 51,516B EV / Sales 2026 *
5.59x
EV / Sales 2027 * 5.18x
Free-Float
91.66%
Yield 2026 *
2.87%
Yield 2027 * 2.99%
Manager TitleAgeSince
Chief Executive Officer 50 31/01/2018
Director of Finance/CFO - 15/03/2026
Compliance Officer 58 13/04/2025
Director TitleAgeSince
Director/Board Member 67 31/12/2014
Director/Board Member 69 31/12/2015
Director/Board Member 61 31/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
-1.52%-7.86%+57.90%+111.09% 1,047B
-0.82%-1.62%+50.05%+62.37% 646B
+0.37%-3.22%+21.87%+72.88% 451B
-1.64%-4.75%+35.59%+35.54% 355B
-0.39%-2.76%+21.39%+38.01% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-0.59%-3.15%+49.83%+67.70% 234B
-1.05%-2.29%-19.91%-54.10% 203B
+0.45%-0.27%+29.84%+91.34% 181B
Average -0.51%-2.68%+27.56%+48.48% 406.59B
Weighted average by Cap. -0.37%-3.46%+36.91%+64.88%

Financials

2026 *2027 *
Net sales 57.65B 49.62B 46.6B 42.55B 79.87B 5,485B 80.45B 552B 215B 2,783B 216B 212B 9,210B 61.31B 52.77B 49.55B 45.25B 84.94B 5,834B 85.56B 587B 228B 2,959B 230B 225B 9,794B
Net income 13.95B 12.01B 11.28B 10.3B 19.33B 1,327B 19.47B 134B 51.93B 673B 52.38B 51.24B 2,229B 15.5B 13.34B 12.53B 11.44B 21.48B 1,475B 21.63B 148B 57.7B 748B 58.2B 56.94B 2,476B
Net Debt 32.68B 28.13B 26.41B 24.12B 45.28B 3,110B 45.61B 313B 122B 1,577B 123B 120B 5,221B 27.82B 23.94B 22.48B 20.53B 38.54B 2,647B 38.82B 266B 104B 1,343B 104B 102B 4,444B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA